# DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

Study · id `cardio:ct-nct05701917` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05701917](<https://clinicaltrials.gov/study/NCT05701917>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05701917

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05701917. Randomized; no masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2028-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05701917, source copy `cardio:ctgov-nct05701917-2026-11-03`, retrieved 2026-11-18)
- Started: 2023-01-06 (actual) (ClinicalTrials.gov record NCT05701917, source copy `cardio:ctgov-nct05701917-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT05701917, source copy `cardio:ctgov-nct05701917-2026-11-03`, retrieved 2026-11-18)
- Completion: 2028-07-31 (anticipated) (ClinicalTrials.gov record NCT05701917, source copy `cardio:ctgov-nct05701917-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Austria; Finland; Germany; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05701917, source copy `cardio:ctgov-nct05701917-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05701917-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
- Acronym: DEFIANCE
- Condition: Venous Thromboembolism
- Condition: Deep Venous Thrombosis
- Condition: Post-Thrombotic Syndrome
- Intervention (Device): ClotTriever System
- Intervention (Drug): Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
- Lead sponsor: Inari Medical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry lists this organization as the lead sponsor: Inari Medical (`cardio:org-inari-medical`)

## Provenance

Content hash: ea47123c1e7c61e504672c8352dcffcf33c28adffda0deec0c72d57bc33bd7df
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
